Aquestive Therapeutics: Rating Downgrade Despite Probability Of Anaphylm Approval
Source: SeekingAlpha
2026-06-04 17:00:10 ET
Investment Overview: Update Since My Last Post - Anaphylm Denied FDA Approval
The last time I covered Aquestive Therapeutics, Inc. ( AQST ) in a note for Seeking Alpha, it was September 2025 , and the Warren, New Jersey-headquartered biotech's stock had just jumped from ~$3.5 per share to ~$5.5 per share on news that the FDA had chosen not to convene an advisory committee ("AdCom") to discuss the approval of its drug candidate Anaphylm (dibutepinephrine) sublingual film. Anticipating an approval in January, I gave the stock a Buy rating....
Read the full article on Seeking Alpha
For further details see:
Aquestive Therapeutics: Rating Downgrade Despite Probability Of Anaphylm Approval
Aquestive Therapeutics Inc.
NASDAQ: AQST
AQST Trading
-3.83% G/L:
$4.015 Last:
585,786 Volume:
$4.14 Open:
AQST Latest News
May 13, 2026 04:01:00 pm
Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026 09:31:25 am
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree
AQST Stock Data
$477,556,785
111,815,853
0.67%
63
N/A
Pharmaceuticals
Healthcare
US
Warren
